The prognosis analysis of epidermal growth factor receptor tyrosine kinase inhibitor targeted treatment combined with chemotherapy in smokers with non-small cell lung cancer.
Administering epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) tyrosine kinase inhibitor (TKI) combined with chemotherapy in patients with non-small cell lung cancer (NSCLC) is a common treatment strategy. However, the prognostic factors for the EGFR-TKI combined with chemotherapy in smokers with NSCLC are still uncertain. In this retrospective study, we enrolled patients with stage IV NSCLC diagnosed between June 2011 and March 2015 at two university-affiliated hospitals in China. Basic characteristics including age, sex, smoking status, performance status, EGFR mutation status, tumor response, and progression-free survival were recorded. A total of 72 patients with stage IV NSCLC with susceptible EGFR gene mutations who had been treated with EGFR-TKI combined with chemotherapy were enrolled. Survival analysis using the Kaplan-Meier method and log-rank test showed a significant difference when classifying the patients according to age and sex (P = 0.0179). When stratifying the patients by sex, a significant difference was found between males and females (1.87 vs 4.87 months; P = 0.0081). A reduced multivariate model developed using the backward variable selection method showed that advanced age remained an independent poor prognostic factor for NSCLC patients, and that sex and advanced age remained independent poor prognostic factors for NSCLC patients (hazard ratio = 3.386, 95% confidence interval: 1.015-11.298, P = 0.0473). This study is the first to demonstrate that female elderly patients have a poorer prognosis if they have received EGFR-TKI combined with chemotherapy. Further large-scale studies are urgently needed to elucidate the mechanism.